Impact of pre-operative transarterial embolization on the treatment of hepatocellular carcinoma with liver transplantation

Table 1 Demographics of patients with hepatocellular carcinoma for liver transplantation.

	TAE (group A, %)	No TAE (group B, %)	P
Number of patient	19 (66)	10 (34)
Age (yr) (mean±SD)	52.4±7.61	45.5±9.89	0.045
Follow-up time (d)	769±395	708±403	0.697
Time from diagnosis to	19.7±18.2	12.6±12.7	0.281
liver transplant
Male/Female	19 (100)/0 (0)	9 (90)/1 (10)	0.345
Hepatitis virus			0.787
Hepatitis B	14 (74)	7 (70)
Hepatitis C	4 (21)	3 (30)
Hepatitis B & C	1 (5)	0 (0)
Initial tumor size (cm)			0.597
< = 3 cm (number of patient)	12 (63)	8 (80)
>3, < = 5 cm	4 (21)	2 (20)
>5 cm	3 (16)	0 (0)
Tumor number			0.481
1 nodule	9 (47)	7 (70)
2 nodule	7 (37)	2 (20)
3 nodule	1 (5)	1 (10)
>3 nodule	2 (11)	0
TAE (number of courses)
1 (number of patient)	10 (53)	--
2	3 (16)	--
>2	6 (32)	--
Above Milan criteria before TAE or transplantation	71 (group A2)	--

¹All downgraded below Milan criteria after TAE.